abstract |
The present invention relates to triterpene glycoside saponin-derived adjuvants, their synthesis, intermediates thereto, and uses thereof. QS-7 is a potent immune-adjuvant that is significantly less toxic than the related saponin QS-21, an adjuvant currently advantageously used in anti-cancer and anti-viral vaccines. The clinical development of QS-7 has been hampered by tedious isolation and purification protocols. A novel semi-synthetic method for synthesizing QS-7, QS-21 and related analogs using hydrolyzed prosapogenin mixtures has been provided, greatly enhancing the approach to QS-7 and QS-21 analogs for preclinical and clinical evaluation. Make it easier. |